Treatment News : Brief Treatment Interruptions for Cure Studies Are Safe, Well-Tolerated

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » November 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


November 2, 2012

Brief Treatment Interruptions for Cure Studies Are Safe, Well-Tolerated

A new study has shown that short treatment interruptions of antiretroviral (ARV) regimens are both safe and well-tolerated among people with HIV. This is good news for scientists pursuing functional cures because they can use such windows to study novel agents that would suppress the virus without an ARV regimen. University of Minnesota researchers presented their findings as a poster abstract at the IDWeek 2012 meeting in San Diego. They studied 14 HIV-positive people with a CD4 count above 350 and an undetectable viral load, all of whom were on stable ARV regimens. After stopping the subjects’ HIV medications, the researchers carefully monitored their CD4 counts and viral loads until HIV RNA was detectable in the blood, at which point the researchers took samples of the HIV reservoir, performed a genotyping test and then reinitiated ARVs. The average study participant took two weeks to reach a detectable viral load and another two weeks to reach full viral suppression once again. All subjects reached virologic suppression. None saw their CD4 levels change significantly; none suffered physical symptoms with the viral load’s return; and none developed drug-resistance or experienced virologic failure.

To read the poster abstract, click here.

Search: HIV, cure, cure research, short treatment interruptions, STI, antiretroviral, ARV, CD4, regimen, virologic suppression, genotyping test, RNA, Unniversity of Minnesota, IDWeek 2012, San Diego.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 1 (of 1 total)    

TIMBIT, nyc, 2012-11-14 12:10:03
This is great news! It suggests a great way to lower the medication burden. For example something like 6 weeks on the meds and 2 weeks off. So in a given 12 month period that would be 3 months without the drugs. This could drastically reduce side effects...

comments 1 - 1 (of 1 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.